Latest / Community Health Media
Dr. Megan Kruse & Dr. Lukas Delasos - ADC Integration & Toxicity in Breast and Thoracic Oncology
As the ADC landscape expands, how is datopotamab deruxtecan redefining the treatment paradigm for both breast and lung cancer?
In this episode of CHM Conversations, Dr. Megan Kruse and Dr. Lukas Delasos break down the clinical integration of next-generation ADCs. The discussion differentiates the roles of ADCs such as datopotamab deruxtecan and trastuzumab deruxtecan, examining their impact across HER2-directed and Trop-2 targeted settings in both metastatic breast cancer and thoracic oncology.
Beyond the data, the clinicians share practical insights on navigating sequencing challenges…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.